Breast Cancer Response to Endocrine Therapy and Immunostaining
Author Information
Author(s): E. Heyderman, S.R. Ebbs, S.E. Larkin, B.M.E. Brown, A.M.R. Haines, T. Bates
Primary Institution: St Thomas Hospital, London
Hypothesis
Can immunostaining of fine needle aspirates predict the response of breast carcinoma to endocrine therapy?
Conclusion
Immunostaining for the oestrogen receptor-related protein P29 can predict the response to endocrine therapy in breast cancer patients.
Supporting Evidence
- 74% of aspirates were suitable for immunostaining.
- 92% of D5-positive patients responded or had static disease.
- 43% of D5-negative tumours responded or remained static.
Takeaway
Doctors can use a special test on breast cancer samples to see if a treatment will work, helping them choose the best care for patients.
Methodology
Fine needle aspirates from patients were immunostained and analyzed for response to endocrine therapy.
Limitations
The study had a small sample size and potential false negatives due to sampling error.
Participant Demographics
Patients included 8 with early breast cancer (ages 70-85) and 18 with advanced breast cancer (ages 44-92).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website